{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:01:45Z","timestamp":1787169705091,"version":"build-2736575974"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Interstitial lung disease and pulmonary sarcoidosis (ILD and PS) and lung cancer represent significant global health threats. Limited research has examined the disease burden and temporal trends of ILD and PS lung cancer among adolescents and young adults (aged 15\u201339\u202fyears). This study aimed to assess the burden of ILD and PS lung cancer in China, analyze contributing factors, compare this burden with other G20 nations, and forecast future disease trends in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>For ILD and PS lung cancer in China, we established incidence, prevalence, mortality, and disability-adjusted life years (DALYs) by executing data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021. Analyses that were comparative to other G20 nations were carried out. Estimated annual percentage changes (EAPCs) were used to assess temporal trends in age-standardized rates (ASRs). Decomposition analysis quantified drivers of burden changes. Furthermore, autoregressive integrated moving average (ARIMA) models projected incidence, mortality, and DALY rates for ILD and PS lung cancer in China from 2021 to 2050.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between 1990 and 2021, China experienced a steady decline in the age-standardized prevalence rate (ASPR), incidence rate (ASIR), death rate (ASDR), and disability-adjusted life years (DALY) rate for ILD and PS. The estimated annual percentage change (EAPC) values were \u22122.5 (95% CI: \u20132.9 to \u22122.1) for ASPR, \u22122.1 (95% CI: \u20132.5 to\u20131.8) for ASIR, \u20130.55 (95% CI: \u20130.71 to \u22120.39) for ASDR, and \u20131.2 (95% CI: \u22121.3 to \u22121.2) for the age-standardized DALY rate. According to 2021 data, among G20 nations, China ranked 19th in ASPR and ASIR for ILD and PS, while it ranked 20th in both ASDR and DALY rate. In contrast, the burden of lung cancer remained consistently high. With the exception of ASPR, which ranked second, all other burden indicators for lung cancer were the highest among G20 countries, with corresponding EAPCs of 0.22 (95% CI: 0.02 to 0.41) for ASPR, \u22120.52 (95% CI: \u20130.71 to \u22120.34) for ASIR, \u22120.98 (95% CI: \u20131.18 to\u20130.78) for ASDR, and \u22121.01 (95% CI:\u20131.19 to \u22120.83) for the age-standardized DALY rate. Decomposition analysis further revealed that shifts in epidemiological patterns were the key factor curbing the rise in absolute numbers of prevalence, incidence, deaths, and DALYs for ILD and PS in China, whereas population growth served as the primary driver increasing the prevalence and incidence of lung cancer. Model-based projections indicate that over the next 29\u202fyears, the ASPR, ASIR, ASDR, and age-standardized DALY rate for both ILD and PS lung cancer in China are expected to continue declining.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ILD and PS lung cancer impose substantial epidemiological burdens across G20 countries, including China. This pressing reality necessitates coordinated multinational efforts to establish collaborative research frameworks, integrate healthcare resources, optimize early screening protocols, and jointly develop evidence-based prevention and control strategies to address this critical public health challenge.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1680118","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T05:26:07Z","timestamp":1765344367000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["The burden of interstitial lung disease and pulmonary sarcoidosis lung cancer among adolescents and young adults from 1990 to 2021 and its projections: a comparative study between China and other G20 countries"],"prefix":"10.3389","volume":"12","author":[{"given":"Long","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinglian","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0140-6736(22)01052-2","article-title":"Interstitiallungdiseases","volume":"400","author":"Wijsenbeek","year":"2022","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1701554","DOI":"10.1183\/13993003.01554-2017","article-title":"Spectrum of interstitial lung disease in China from 2000 to 2012","volume":"52","author":"Ban","year":"2018","journal-title":"Eur Respir J"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"4100","DOI":"10.1007\/s12325-021-01786-8","article-title":"Prevalence and incidence of chronic Fibrosing interstitial lung diseases with a progressive phenotype in the United States estimated in a large claims database analysis","volume":"38","author":"Olson","year":"2021","journal-title":"Adv Ther"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/s12890-021-01783-1","article-title":"Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis","volume":"21","author":"Finnerty","year":"2021","journal-title":"BMC Pulm Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.chest.2022.11.035","article-title":"Treatment outcomes for rheumatoid arthritis-associated interstitial lung disease: a real-world, multisite study of the impact of immunosuppression on pulmonary function trajectory","volume":"163","author":"Matson","year":"2023","journal-title":"Chest"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"17534666231165912","DOI":"10.1177\/17534666231165912","article-title":"Anti-fibrotic therapy and lung transplant outcomes in patients with idiopathic pulmonary fibrosis","volume":"17","author":"Astor","year":"2023","journal-title":"Ther Adv Respir Dis"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.bbcan.2015.08.002","article-title":"Lung cancer: biology and treatment options","volume":"1856","author":"Lemjabbar-Alaoui","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.1002\/cncr.33078","article-title":"Global, regional, and national burden of lung cancer and its attributable risk factors, 1990 to 2017","volume":"126","author":"Wang","year":"2020","journal-title":"Cancer"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"102232","DOI":"10.1016\/j.canep.2022.102232","article-title":"Trends in incidence and mortality of lung cancer in Switzerland: possible explanations and open questions","volume":"80","author":"Frisone","year":"2022","journal-title":"Cancer Epidemiol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21147\/j.issn.1000-9604.2018.01.01","article-title":"Cancer incidence and mortality in China, 2014","volume":"30","author":"Chen","year":"2018","journal-title":"Chin J Cancer Res"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.3390\/pharmaceutics15041252","article-title":"Clinical relevance of targeted therapy and immune-checkpoint inhibition in lung Cancer","volume":"15","author":"Leone","year":"2023","journal-title":"Pharmaceutics"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13045-022-01391-4","article-title":"Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance","volume":"15","author":"Fu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"8362","DOI":"10.7150\/thno.39816","article-title":"Strategy to enhance lung cancer treatment by five essential elements: inhalation delivery, nanotechnology, tumor-receptor targeting, chemo- and gene therapy","volume":"9","author":"Garbuzenko","year":"2019","journal-title":"Theranostics"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1002\/cncr.29603","article-title":"Increased lung cancer mortality rates in the Chinese population from 1973-1975 to 2004-2005: an adverse health effect from exposure to smoking","volume":"121","author":"Zhi","year":"2015","journal-title":"Cancer"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.21037\/jtd.2018.05.75","article-title":"Lung cancer and interstitial lung disease: a literature review","volume":"10","author":"Naccache","year":"2018","journal-title":"J Thorac Dis"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"100396","DOI":"10.1016\/j.onehlt.2022.100396","article-title":"Strengthening preparedness against global health threats: a paradigm shift based on one health approaches","volume":"14","author":"Dente","year":"2022","journal-title":"One Health"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1186\/s12889-019-7114-5","article-title":"Soft power and global health: the sustainable development goals (SDGs) era health agendas of the G7, G20 and BRICS","volume":"19","author":"McBride","year":"2019","journal-title":"BMC Public Health"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1186\/s12884-025-07617-w","article-title":"Trends in burden and mortality of congenital birth defects in G20 countries (1990\u20132021) and predictions for 2022\u20132040","volume":"25","author":"Li","year":"2025","journal-title":"BMC Pregnancy Childbirth"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e1003138","DOI":"10.1371\/journal.pmed.1003138","article-title":"Population ageing and mortality during 1990-2017: a global decomposition analysis","volume":"17","author":"Cheng","year":"2020","journal-title":"PLoS Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12889-023-15050-x","article-title":"Disease burden and attributable risk factors of neonatal disorders and their specific causes in China from 1990 to 2019 and its prediction to 2024","volume":"23","author":"Wu","year":"2023","journal-title":"BMC Public Health"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1578480","DOI":"10.3389\/fpubh.2025.1578480","article-title":"Global, regional, and national burden of interstitial lung diseases and pulmonary sarcoidosis from 2000 to 2021: a systematic analysis of incidence, mortality, and disability-adjusted life years","volume":"13","author":"Zhou","year":"2025","journal-title":"Front Public Health"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/cac2.12393","article-title":"Cancer situation in China: what does the China cancer map indicate from the first national death survey to the latest cancer registration?","volume":"43","author":"Feng","year":"2023","journal-title":"Cancer Commun"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"14663","DOI":"10.3390\/ijerph192214663","article-title":"Prevalence and disability-adjusted life year rates of asthma in China: findings from the GBD study 2019 of the G20","volume":"19","author":"Liu","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.chest.2023.11.037","article-title":"Pictorial review of fibrotic interstitial lung disease on high-resolution CT scan and updated classification","volume":"165","author":"Brixey","year":"2024","journal-title":"Chest"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"4631","DOI":"10.3390\/jcm11154631","article-title":"New era in systemic sclerosis treatment: recently approved therapeutics","volume":"11","author":"Ebata","year":"2022","journal-title":"J Clin Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1216924","DOI":"10.3389\/fpubh.2023.1216924","article-title":"Current status, trends, and predictions in the burden of silicosis in 204 countries and territories from 1990 to 2019","volume":"11","author":"Yi","year":"2023","journal-title":"Front Public Health"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1001\/jama.290.24.3229","article-title":"Ethical and legal challenges posed by severe acute respiratory syndrome: implications for the control of severe infectious disease threats","volume":"290","author":"Gostin","year":"2003","journal-title":"JAMA"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"m234","DOI":"10.1136\/bmj.m234","article-title":"Trends and risk factors of mortality and disability adjusted life years for chronic respiratory diseases from 1990 to 2017: systematic analysis for the Global Burden of Disease Study 2017","volume":"368","author":"Li","year":"2020","journal-title":"BMJ"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"l2231","DOI":"10.1136\/bmj.l2231","article-title":"Cigarette consumption estimates for 71 countries from 1970 to 2015: systematic collection of comparable data to facilitate quasi-experimental evaluations of national and global tobacco control interventions","volume":"365","author":"Hoffman","year":"2019","journal-title":"BMJ"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e191474","DOI":"10.1001\/jamanetworkopen.2019.1474","article-title":"Tobacco smoking and mortality in Asia: a pooled meta-analysis","volume":"2","author":"Yang","year":"2019","journal-title":"JAMA Netw Open"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/s1473-3099(22)00510-2","article-title":"Age-sex differences in the global burden of lower respiratory infections and risk factors, 1990-2019: results from the global burden of disease study 2019","volume":"22","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.amepre.2017.02.006","article-title":"Smoking-cessation assistance: before and after stage 1 meaningful use implementation","volume":"53","author":"Bailey","year":"2017","journal-title":"Am J Prev Med"},{"key":"ref35","first-page":"15","article-title":"2018 China adult tobacco survey report","volume":"30","year":"2018","journal-title":"Bei Jing"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"e618","DOI":"10.1016\/s2468-2667(19)30203-8","article-title":"Smoking prevalence following tobacco tax increases in Australia between 2001 and 2017: an interrupted time-series analysis","volume":"4","author":"Wilkinson","year":"2019","journal-title":"Lancet Public Health"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1161\/circulationaha.117.029380","article-title":"Divining the future of air pollution in China: huge gains in health can be achieved, but much work remains","volume":"136","author":"Bell","year":"2017","journal-title":"Circulation"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.envint.2019.04.026","article-title":"Globally analysing spatiotemporal trends of anthropogenic PM(2.5) concentration and population's PM(2.5) exposure from 1998 to 2016","volume":"128","author":"Li","year":"","journal-title":"Environ Int"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1289\/ehp\/1408092","article-title":"Outdoor particulate matter exposure and lung cancer: a systematic review and meta-analysis","volume":"122","author":"Hamra","year":"2014","journal-title":"Environ Health Perspect"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/s2213-2600(14)70168-7","article-title":"Respiratory risks from household air pollution in low and middle income countries","volume":"2","author":"Gordon","year":"2014","journal-title":"Lancet Respir Med"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"e8313","DOI":"10.15252\/emmm.201708313","article-title":"Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancer","volume":"10","author":"Ali","year":"2018","journal-title":"EMBO Mol Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1680118\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T05:26:08Z","timestamp":1765344368000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1680118\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":41,"alternative-id":["10.3389\/fmed.2025.1680118"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1680118","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"article-number":"1680118"}}